Ajanta Pharma Q2FY27: consolidated PAT +49% YoY as margins beat guidance
PAT +49.18% YoY · revenue +32.54% · margins expanding
₹1,794.16 Cr
+32.54% YoY
₹388.14 Cr
+49.18% YoY
21.19%
+2.8pp YoY
₹31.07
Consolidated PAT for Q2 FY27 came in at ₹388 Cr, up 49% YoY (₹260 Cr) and 16% QoQ (₹334 Cr), on revenue from operations of ₹1,794 Cr, up 33% YoY and 10% QoQ. Net profit margin expanded to 21.6% from 18.4% a year ago and 19.7% last quarter. Standalone PAT was ₹380 Cr, up 52% YoY — standalone and consolidated tell the same growth story with no material divergence. Neither this quarter nor the year-ago quarter carries an exceptional item, so the YoY growth is clean rather than base-effect driven.
Q2 FY-2027 vs prior quarters
Segment-wise, US Generics led with revenue up 41% YoY to ₹484 Cr, Africa Institution (tender-driven) revenue jumped to ₹116 Cr from ₹32 Cr (+259% YoY), and India branded generics grew a steadier 16% YoY to ₹504 Cr — ahead of IPM industry growth of 13% per IQVIA MAT September 2026 data, against Ajanta's own 17% India branded growth. Gross margin held at 78.5%, within management's guided ~78%±1% band, while adjusted EBITDA margin (excluding forex) rose to 30% from 24.2% a year ago — above the ~27%±1% full-year EBITDA guidance given on the Q3 FY26 call. The expansion is broad-based across segments rather than a single cost-line effect.
The stock went into the print at ₹3,527.1, down 0.9% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.
Management guided for overall mid-teens revenue growth for FY26, with Asia expected at mid-single to high-single digits and Africa at low-double digits. For FY27, US generics are projected for double-digit growth, albeit not at the current robust pace. Gross margins are expected to remain around 78% +/- 1% and EBITDA m
— This quarter: beat
On the January 2026 concall, management had guided US generics to grow in double digits for FY27 but "not at the current robust pace" — this quarter's 41% YoY US print shows that expected deceleration has not materialised yet. No Q2-specific published Street consensus was found; full-year FY27 analyst consensus pegs revenue growth at roughly 15% YoY (₹6,270 Cr), a pace H1 FY27's 29% YoY growth is already running well ahead of. The quarter also saw routine promoter-level pledge/release filings (a 30,000-share pledge on Oct 21, a 2.10% stake pledge by CTL Trusteeship on Oct 1, an NCD-linked pledge on Oct 6, and a 98,185-share release on Sep 28) — financing-related disclosures unconnected to the operating numbers.
W1
Africa Institution tender revenue (₹116 Cr this quarter, ₹187 Cr for H1) — whether it normalises or stays elevated next quarter
W2
US Generics growth pace (41% YoY this quarter) — management guided FY27 deceleration to double digits; watch if that shows up in Q3
W3
H1 FY27 adjusted EBITDA margin of 29.1% (₹997 Cr/₹3,420 Cr) vs full-year guidance of ~27%±1% — whether H2 margins hold near this beat
Clean statement, both totals tie exactly (totalIncome = revenue+other income; PAT = PBT-tax). No exceptional-items line; forex gains/losses sit inside other income/other expense (company separately reports EBITDA ex-forex). Consolidated has no minority interest.
Informational and educational content only. Not investment advice.